David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

In a Time of Transition, Asensus Surgical Stock Remains a Worthy Investment

By David Moadel, InvestorPlace Contributor

Before you consider investing in ASXC stock, you'll definitely want to be aware of the important changes going on in the stock and company.

Roblox Stock Is Set For Growth as the Company Targets Older Users

By David Moadel, InvestorPlace Contributor

Some investors might avoid RBLX stock because they feel that the Roblox platform is just for kids, but the company is proving them wrong.

Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings Release

By David Moadel, InvestorPlace Contributor

CODX stock's true value isn't fully appreciated by the investing community, and this could provide a setup for an explosive move.

Combine Cannabis and Real Estate With Innovative Industrial Properties

By David Moadel, InvestorPlace Contributor

IIPR stock isn't a direct play on the cannabis market, nor is it the cheapest stock. Yet, it's a worthy investment in a growing industry.

Wait for Acasti Pharma Stock to Fall Further Before Buying

By David Moadel, InvestorPlace Contributor

The future course of ACST stock depends largely on the company's lead drug candidate, CaPre. Any good news could send the shares higher.

Load More